Melioidosis: Evolving Concepts in Epidemiology, Pathogenesis, and Treatment

Abstract Infection with Burkholderia pseudomallei can result in asymptomatic seroconversion, a single skin lesion that may or may not heal spontaneously, a pneumonia which can be subacute or chronic and mimic tuberculosis or rapidly progressive resulting in fatal overwhelming sepsis. Latency with subsequent activation of disease is well recognized, but very uncommon. Melioidosis also has a myriad of other clinical presentations and diagnosis is often delayed because of this and because of difficulties with laboratory diagnosis and lack of recognition outside melioidosis-endemic regions. The perception of B. pseudomallei as a top tier biothreat agent has driven large funding for research, yet resources for diagnosis and therapy of melioidosis in many endemic locations remain extremely limited, with mortality as high as 50% in comparison to around 10% in regions where state-of-the-art intensive care therapy for sepsis is available. Fatal melioidosis is extremely unlikely from natural infection in a healthy person, provided the diagnosis is made early, ceftazidime or meropenem is commenced and intensive care therapy is available. While biothreat research is directed toward potential aerosol exposure to B. pseudomallei, the overall proportion of melioidosis cases resulting from inhalation rather than from percutaneous inoculation remains entirely uncertain, although the epidemiology supports a shift to inhalation during severe weather events such as cyclones and typhoons. What makes B. pseudomallei such a dangerous organism for patients with diabetes and other selective risk factors remains unclear, but microbial genome-wide association studies linking clinical aspects of melioidosis cases to nonubiquitous or polymorphic B. pseudomallei genes or genomic islands are beginning to uncover specific virulence signatures. Finally, what also remains uncertain is the global phylogeography of B. pseudomallei and whether melioidosis is spreading beyond historical locations or is just being unmasked in Africa and the Americas by better recognition and increased surveillance.

[1]  L. Waller,et al.  Contact investigation of melioidosis cases reveals regional endemicity in Puerto Rico. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  P. Newton,et al.  Trimethoprim/sulfamethoxazole resistance in Burkholderia pseudomallei , 2014, International journal of antimicrobial agents.

[3]  B. Currie,et al.  Autochthonous Melioidosis in Humans, Madagascar, 2012 and 2013 , 2014, Emerging infectious diseases.

[4]  K. Fuursted,et al.  Mycotic aneurysm caused by Burkholderia pseudomallei in a previously healthy returning traveller , 2014, BMJ Case Reports.

[5]  H. D. Liggitt,et al.  NLRC4 and TLR5 Each Contribute to Host Defense in Respiratory Melioidosis , 2014, PLoS neglected tropical diseases.

[6]  B. Currie,et al.  Current antimicrobial susceptibility of first-episode melioidosis Burkholderia pseudomallei isolates from the Northern Territory, Australia. , 2014, International journal of antimicrobial agents.

[7]  A. Hoffmaster,et al.  Fatal Burkholderia pseudomallei infection initially reported as a Bacillus species, Ohio, 2013. , 2014, The American journal of tropical medicine and hygiene.

[8]  Pei-Shih Chen,et al.  The Concentrations of Ambient Burkholderia Pseudomallei during Typhoon Season in Endemic Area of Melioidosis in Taiwan , 2014, PLoS Neglected Tropical Diseases.

[9]  A. Mackay-Sim,et al.  Burkholderia pseudomallei Penetrates the Brain via Destruction of the Olfactory and Trigeminal Nerves: Implications for the Pathogenesis of Neurological Melioidosis , 2014, mBio.

[10]  A. Hoffmaster,et al.  Burkholderia pseudomallei Type G in Western Hemisphere , 2014, Emerging infectious diseases.

[11]  D. Dance,et al.  International Journal of Antimicrobial Agents Review Treatment and Prophylaxis of Melioidosis , 2022 .

[12]  Erin P. Price,et al.  Variable Virulence Factors in Burkholderia pseudomallei (Melioidosis) Associated with Human Disease , 2014, PloS one.

[13]  N. Day,et al.  Trimethoprim-sulfamethoxazole versus trimethoprim-sulfamethoxazole plus doxycycline as oral eradicative treatment for melioidosis (MERTH): a multicentre, double-blind, non-inferiority, randomised controlled trial , 2014, The Lancet.

[14]  Direk Limmathurotsakul,et al.  Development of a Prototype Lateral Flow Immunoassay (LFI) for the Rapid Diagnosis of Melioidosis , 2014, PLoS neglected tropical diseases.

[15]  T. West,et al.  Common TLR1 Genetic Variation Is Not Associated with Death from Melioidosis, a Common Cause of Sepsis in Rural Thailand , 2014, PloS one.

[16]  H. D. Liggitt,et al.  The Role of NOD2 in Murine and Human Melioidosis , 2014, The Journal of Immunology.

[17]  T. West,et al.  Screen of whole blood responses to flagellin identifies TLR5 variation associated with outcome in melioidosis , 2013, Genes and Immunity.

[18]  B. Currie,et al.  Recurrent Melioidosis in the Darwin Prospective Melioidosis Study: Improving Therapies Mean that Relapse Cases Are Now Rare , 2013, Journal of Clinical Microbiology.

[19]  N. Day,et al.  Rapid Detection of Burkholderia pseudomallei in Blood Cultures Using a Monoclonal Antibody-Based Immunofluorescent Assay , 2013, The American journal of tropical medicine and hygiene.

[20]  T. William,et al.  Reliability of Automated Biochemical Identification of Burkholderia pseudomallei Is Regionally Dependent , 2013, Journal of Clinical Microbiology.

[21]  A. Cheng,et al.  Osteomyelitis and septic arthritis from infection with Burkholderia pseudomallei: A 20-year prospective melioidosis study from northern Australia. , 2013, Journal of orthopaedics.

[22]  R. Heyderman,et al.  Human Melioidosis, Malawi, 2011 , 2013, Emerging infectious diseases.

[23]  T. West,et al.  Impaired TLR5 Functionality Is Associated with Survival in Melioidosis , 2013, The Journal of Immunology.

[24]  B. Currie,et al.  Surprisingly Low Seroprevalence of Burkholderia pseudomallei in Exposed Healthy Adults in the Darwin Region of Tropical Australia Where Melioidosis Is Highly Endemic , 2013, Clinical and Vaccine Immunology.

[25]  Xiangyang Liu,et al.  Genomics-guided discovery of thailanstatins A, B, and C As pre-mRNA splicing inhibitors and antiproliferative agents from Burkholderia thailandensis MSMB43. , 2013, Journal of natural products.

[26]  A. Simpson,et al.  Clinical Definitions of Melioidosis , 2013, The American journal of tropical medicine and hygiene.

[27]  B. Currie,et al.  Melioidosis and the kidney , 2013, Nephrology.

[28]  Robin Patel,et al.  Importance of Using Bruker's Security-Relevant Library for Biotyper Identification of Burkholderia pseudomallei, Brucella Species, and Francisella tularensis , 2013, Journal of Clinical Microbiology.

[29]  J. Vadivelu,et al.  Burkholderia vaccines: are we moving forward? , 2013, Front. Cell. Inf. Microbio..

[30]  N. Day,et al.  Activities of Daily Living Associated with Acquisition of Melioidosis in Northeast Thailand: A Matched Case-Control Study , 2013, PLoS neglected tropical diseases.

[31]  N. Ketheesan,et al.  ELISA and immuno-polymerase chain reaction assays for the sensitive detection of melioidosis. , 2013, Diagnostic microbiology and infectious disease.

[32]  H. D. Liggitt,et al.  Murine pulmonary infection and inflammation induced by inhalation of Burkholderia pseudomallei , 2012, International journal of experimental pathology.

[33]  Theresa L. Smith,et al.  Workshop on Treatment of and Postexposure Prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010 , 2012, Emerging infectious diseases.

[34]  G. Maneenil,et al.  Neonatal Melioidosis: Systematic Review of the Literature , 2012, The Pediatric infectious disease journal.

[35]  D. Butler Viral research faces clampdown , 2012, Nature.

[36]  H. Schweizer When it comes to drug discovery not all Gram‐negative bacterial biodefence pathogens are created equal: Burkholderia pseudomallei is different , 2012, Microbial biotechnology.

[37]  P. Keim,et al.  Out of the ground: aerial and exotic habitats of the melioidosis bacterium Burkholderia pseudomallei in grasses in Australia. , 2012, Environmental microbiology.

[38]  Talima Pearson,et al.  Comparison of TaqMan PCR Assays for Detection of the Melioidosis Agent Burkholderia pseudomallei in Clinical Specimens , 2012, Journal of Clinical Microbiology.

[39]  U. Parameswaran,et al.  Melioidosis at Royal Darwin Hospital in the big 2009–2010 wet season: comparison with the preceding 20 years , 2012, The Medical journal of Australia.

[40]  D. Engelthaler,et al.  Characterization of Ceftazidime Resistance Mechanisms in Clinical Isolates of Burkholderia pseudomallei from Australia , 2012, PloS one.

[41]  A. Cheng,et al.  Clinical features and epidemiology of melioidosis pneumonia: results from a 21-year study and review of the literature. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  H. Schweizer,et al.  Proteomic analysis of colony morphology variants of Burkholderia pseudomallei defines a role for the arginine deiminase system in bacterial survival , 2012, Journal of proteomics.

[43]  N. Day,et al.  Melioidosis Vaccines: A Systematic Review and Appraisal of the Potential to Exploit Biodefense Vaccines for Public Health Purposes , 2012, PLoS neglected tropical diseases.

[44]  A. Simpson,et al.  Development of an acute model of inhalational melioidosis in the common marmoset (Callithrix jacchus) , 2011, International journal of experimental pathology.

[45]  D. Rice,et al.  A Burkholderia pseudomallei Toxin Inhibits Helicase Activity of Translation Factor eIF4A , 2011, Science.

[46]  H. Schweizer,et al.  Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei , 2011, Proceedings of the National Academy of Sciences.

[47]  L. Price,et al.  Molecular Investigations of a Locally Acquired Case of Melioidosis in Southern AZ, USA , 2011, PLoS neglected tropical diseases.

[48]  N. Day,et al.  Survey of Antimicrobial Resistance in Clinical Burkholderia pseudomallei Isolates over Two Decades in Northeast Thailand , 2011, Antimicrobial Agents and Chemotherapy.

[49]  T. West,et al.  Toll-Like Receptor 4 Region Genetic Variants are Associated with Susceptibility to Melioidosis , 2011, Genes and Immunity.

[50]  Theresa L. Smith,et al.  Epidemiology and Investigation of Melioidosis, Southern Arizona , 2011, Emerging infectious diseases.

[51]  H. Atkins,et al.  Antimicrobials for bacterial bioterrorism agents. , 2011, Future microbiology.

[52]  P. Harris,et al.  Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin. , 2011, International journal of antimicrobial agents.

[53]  P. Dawyndt,et al.  Classification and identification of the Burkholderia cepacia complex: Past, present and future. , 2011, Systematic and applied microbiology.

[54]  D. DeShazer,et al.  The Cluster 1 Type VI Secretion System Is a Major Virulence Determinant in Burkholderia pseudomallei , 2011, Infection and Immunity.

[55]  A. Cheng,et al.  The Epidemiology and Clinical Spectrum of Melioidosis: 540 Cases from the 20 Year Darwin Prospective Study , 2010, PLoS neglected tropical diseases.

[56]  N. Day,et al.  Increasing Incidence of Human Melioidosis in Northeast Thailand , 2010, The American journal of tropical medicine and hygiene.

[57]  H. Schweizer,et al.  Present and future therapeutic strategies for melioidosis and glanders , 2010, Expert review of anti-infective therapy.

[58]  K. Goh,et al.  Melioidosis in a Tropical City State, Singapore , 2009, Emerging infectious diseases.

[59]  A. Cheng,et al.  Prostatic abscess due to Burkholderia pseudomallei: 81 cases from a 19-year prospective melioidosis study. , 2009, The Journal of urology.

[60]  A. Cheng,et al.  Dosing Regimens of Cotrimoxazole (Trimethoprim-Sulfamethoxazole) for Melioidosis , 2009, Antimicrobial Agents and Chemotherapy.

[61]  A. Mackay-Sim,et al.  Nasal-associated lymphoid tissue and olfactory epithelium as portals of entry for Burkholderia pseudomallei in murine melioidosis. , 2009, The Journal of infectious diseases.

[62]  A. Cheng,et al.  The global distribution of Burkholderia pseudomallei and melioidosis: an update. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[63]  A. Haque,et al.  Burkholderia pseudomallei: animal models of infection. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[64]  A. Cheng,et al.  Intensity of exposure and incidence of melioidosis in Thai children. , 2008, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[65]  Raymond K. Auerbach,et al.  Genomic islands from five strains of Burkholderia pseudomallei , 2008, BMC Genomics.

[66]  N. Day,et al.  A Simple Scoring System to Differentiate between Relapse and Re-Infection in Patients with Recurrent Melioidosis , 2008, PLoS neglected tropical diseases.

[67]  K. Gibney,et al.  Cutaneous melioidosis in the tropical top end of Australia: a prospective study and review of the literature. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  T. West,et al.  Strategies to Reduce Mortality from Bacterial Sepsis in Adults in Developing Countries , 2008, PLoS medicine.

[69]  Theresa L. Smith,et al.  Management of Accidental Laboratory Exposure to Burkholderia pseudomallei and B. mallei , 2008, Emerging infectious diseases.

[70]  T. Coenye,et al.  Diversity and occurrence of Burkholderia spp. in the natural environment. , 2008, FEMS microbiology reviews.

[71]  Ryan T Novak,et al.  Recovery of a Burkholderia thailandensis-like isolate from an Australian water source , 2008, BMC Microbiology.

[72]  A. Cheng,et al.  Consensus guidelines for dosing of amoxicillin-clavulanate in melioidosis. , 2008, The American journal of tropical medicine and hygiene.

[73]  N. Day,et al.  Loop-Mediated Isothermal Amplification Method Targeting the TTS1 Gene Cluster for Detection of Burkholderia pseudomallei and Diagnosis of Melioidosis , 2007, Journal of Clinical Microbiology.

[74]  Raymond K. Auerbach,et al.  A Horizontal Gene Transfer Event Defines Two Distinct Groups within Burkholderia pseudomallei That Have Dissimilar Geographic Distributions , 2007, Journal of bacteriology.

[75]  P. Newton,et al.  Accuracy of Burkholderia pseudomallei Identification Using the API 20NE System and a Latex Agglutination Test , 2007, Journal of Clinical Microbiology.

[76]  N. Day,et al.  Addition of trimethoprim-sulfamethoxazole to ceftazidime during parenteral treatment of melioidosis is not associated with a long-term outcome benefit. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[77]  A. Cheng,et al.  A randomized controlled trial of granulocyte colony-stimulating factor for the treatment of severe sepsis due to melioidosis in Thailand. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[78]  T. van der Poll,et al.  Toll-Like Receptor 2 Impairs Host Defense in Gram-Negative Sepsis Caused by Burkholderia pseudomallei (Melioidosis) , 2007, PLoS medicine.

[79]  W. Ko,et al.  Melioidosis Outbreak after Typhoon, Southern Taiwan , 2007, Emerging infectious diseases.

[80]  N. Day,et al.  Biological Relevance of Colony Morphology and Phenotypic Switching by Burkholderia pseudomallei , 2006, Journal of bacteriology.

[81]  T. Inglis,et al.  Melioidosis in the Americas. , 2006, The American journal of tropical medicine and hygiene.

[82]  Ryan T Novak,et al.  Clinical Evaluation of a Type III Secretion System Real-Time PCR Assay for Diagnosing Melioidosis , 2006, Journal of Clinical Microbiology.

[83]  N. Day,et al.  Development of antibodies to Burkholderia pseudomallei during childhood in melioidosis-endemic northeast Thailand. , 2006, The American journal of tropical medicine and hygiene.

[84]  Nicholas J. White,et al.  Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei , 2006, Nature Reviews Microbiology.

[85]  A. Cheng,et al.  Indirect hemagglutination assay in patients with melioidosis in northern Australia. , 2006, The American journal of tropical medicine and hygiene.

[86]  Ryan T Novak,et al.  Development and Evaluation of a Real-Time PCR Assay Targeting the Type III Secretion System of Burkholderia pseudomallei , 2006, Journal of Clinical Microbiology.

[87]  A. Cheng,et al.  Short report: disease severity and outcome of melioidosis in HIV coinfected individuals. , 2005, The American journal of tropical medicine and hygiene.

[88]  P. Newton,et al.  Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[89]  A. Cheng,et al.  Comparison of Ashdown's Medium, Burkholderia cepacia Medium, and Burkholderia pseudomallei Selective Agar for Clinical Isolation of Burkholderia pseudomallei , 2005, Journal of Clinical Microbiology.

[90]  N. Day,et al.  Melioidosis in 6 tsunami survivors in southern Thailand. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[91]  I. Bastian,et al.  Melioidosis in Tsunami Survivors , 2005, Emerging infectious diseases.

[92]  A. Cheng,et al.  Rapid Immunofluorescence Microscopy for Diagnosis of Melioidosis , 2005, Clinical Diagnostic Laboratory Immunology.

[93]  A. Allworth Tsunami lung: a necrotising pneumonia in survivors of the Asian tsunami , 2005, The Medical journal of Australia.

[94]  A. Cheng,et al.  Melioidosis: Epidemiology, Pathophysiology, and Management , 2005, Clinical Microbiology Reviews.

[95]  G. Crawford,et al.  Cutaneous Melioidosis in a Man Who Was Taken as a Prisoner of War by the Japanese during World War II , 2005, Journal of Clinical Microbiology.

[96]  R. Devinney,et al.  The Capsular Polysaccharide of Burkholderia pseudomallei Contributes to Survival in Serum by Reducing Complement Factor C3b Deposition , 2005, Infection and Immunity.

[97]  A. Ralph,et al.  Transmission of Burkholderia pseudomallei via breast milk in northern Australia. , 2004, The Pediatric infectious disease journal.

[98]  R. Ulrich,et al.  Role of quorum sensing in the pathogenicity of Burkholderia pseudomallei. , 2004, Journal of medical microbiology.

[99]  P. Vandamme,et al.  Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe , 2004, Thorax.

[100]  R. Speare,et al.  Adaptive immunity in melioidosis: a possible role for T cells in determining outcome of infection with Burkholderia pseudomallei. , 2004, Clinical immunology.

[101]  Kim Rutherford,et al.  Genomic plasticity of the causative agent of melioidosis, Burkholderia pseudomallei. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[102]  O. White,et al.  Structural flexibility in the Burkholderia mallei genome. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[103]  B. Currie,et al.  The neuropathology of melioidosis: two cases and a review of the literature. , 2004, Clinical neuropathology.

[104]  B. Currie,et al.  Out of hospital treatment of patients with melioidosis using ceftazidime in 24 h elastomeric infusors, via peripherally inserted central catheters , 2004, Tropical medicine & international health : TM & IH.

[105]  N. Anstey,et al.  Outcomes of Patients with Melioidosis Treated with Meropenem , 2004, Antimicrobial Agents and Chemotherapy.

[106]  B. Currie,et al.  Intensity of Rainfall and Severity of Melioidosis, Australia , 2003, Emerging infectious diseases.

[107]  B. Currie Melioidosis: an important cause of pneumonia in residents of and travellers returned from endemic regions , 2003, European Respiratory Journal.

[108]  B. Spratt,et al.  Multilocus Sequence Typing and Evolutionary Relationships among the Causative Agents of Melioidosis and Glanders, Burkholderia pseudomallei and Burkholderia mallei , 2003, Journal of Clinical Microbiology.

[109]  J. Jeddeloh,et al.  Biodefense-Driven Murine Model of Pneumonic Melioidosis , 2003, Infection and Immunity.

[110]  R. Norton,et al.  Comparison of Automated and Nonautomated Systems for Identification of Burkholderia pseudomallei , 2002, Journal of Clinical Microbiology.

[111]  M. Stevens,et al.  An Inv/Mxi‐Spa‐like type III protein secretion system in Burkholderia pseudomallei modulates intracellular behaviour of the pathogen , 2002, Molecular microbiology.

[112]  N. Ketheesan,et al.  Demonstration of a cell-mediated immune response in melioidosis. , 2002, The Journal of infectious diseases.

[113]  Y. Sitoh,et al.  Cerebral melioidosis in Singapore: a review of five cases. , 2002, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[114]  S. Deitchman,et al.  Glanders in a military research microbiologist. , 2001, The New England journal of medicine.

[115]  N. Anstey,et al.  A cluster of melioidosis cases from an endemic region is clonal and is linked to the water supply using molecular typing of Burkholderia pseudomallei isolates. , 2001, The American journal of tropical medicine and hygiene.

[116]  J. Bartlett,et al.  Glanders in a military research microbiologist. , 2001, New England Journal of Medicine.

[117]  N. Ketheesan,et al.  Burkholderia pseudomallei virulence: definition, stability and association with clonality. , 2001, Microbes and infection.

[118]  D. Fisher,et al.  Antibiotic susceptibility of Burkholderia pseudomallei from tropical northern Australia and implications for therapy of melioidosis. , 2001, International journal of antimicrobial agents.

[119]  N. Anstey,et al.  Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[120]  N. Anstey,et al.  Melioidosis: acute and chronic disease, relapse and re-activation. , 2000, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[121]  N. Anstey,et al.  The epidemiology of melioidosis in Australia and Papua New Guinea. , 2000, Acta tropica.

[122]  A. Leelarasamee Melioidosis in Southeast Asia. , 2000, Acta tropica.

[123]  B. Currie,et al.  Animal melioidosis in Australia. , 2000, Acta tropica.

[124]  W. Chaowagul,et al.  Polymorphism in the promoter region of tumor necrosis factor-alpha gene is associated with severe meliodosis. , 1999, Human immunology.

[125]  A. Simpson,et al.  Comparison of imipenem and ceftazidime as therapy for severe melioidosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[126]  Y. Suputtamongkol,et al.  Risk factors for melioidosis and bacteremic melioidosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[127]  A. Simpson,et al.  A comparison of chloramphenicol, trimethoprim-sulfamethoxazole, and doxycycline with doxycycline alone as maintenance therapy for melioidosis. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[128]  D. DeShazer,et al.  The type II O‐antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence , 1998, Molecular microbiology.

[129]  M. Wheelis First shots fired in biological warfare , 1998, Nature.

[130]  N. White,et al.  In-vitro activity of carbapenem antibiotics against beta-lactam susceptible and resistant strains of Burkholderia pseudomallei. , 1996, The Journal of antimicrobial chemotherapy.

[131]  A. Hall,et al.  The epidemiology of melioidosis in Ubon Ratchatani, northeast Thailand. , 1994, International journal of epidemiology.

[132]  N. White,et al.  Relapse in melioidosis: incidence and risk factors. , 1993, The Journal of infectious diseases.

[133]  N. Anstey,et al.  Neurological melioidosis: seven cases from the Northern Territory of Australia. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[134]  N. White,et al.  Development of resistance to ceftazidime and co-amoxiclav in Pseudomonas pseudomallei. , 1991, The Journal of antimicrobial chemotherapy.

[135]  D. Dance Melioidosis: the tip of the iceberg? , 1991, Clinical Microbiology Reviews.

[136]  N. White,et al.  The use of selective media for the isolation of Pseudomonas pseudomallei in clinical practice. , 1990, Journal of medical microbiology.

[137]  N. White,et al.  HALVING OF MORTALITY OF SEVERE MELIOIDOSIS BY CEFTAZIDIME , 1989, The Lancet.

[138]  N. White,et al.  The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. , 1989, The Journal of antimicrobial chemotherapy.

[139]  N. White,et al.  Identification of Pseudomonas pseudomallei in clinical practice: use of simple screening tests and API 20NE. , 1989, Journal of clinical pathology.

[140]  A. Leelarasamee,et al.  Melioidosis: review and update. , 1989, Reviews of infectious diseases.

[141]  N. White,et al.  Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. , 1989, The Journal of infectious diseases.

[142]  N. White,et al.  Acute suppurative parotitis caused by Pseudomonas pseudomallei in children. , 1989, The Journal of infectious diseases.

[143]  N. White,et al.  ANTIBIOTIC RESISTANCE IN PSEUDOMONAS PSEUDOMALLEI , 1988, The Lancet.

[144]  K. Silpapojakul,et al.  Acute Pseudomonas pseudomallei pneumonia and septicemia following aspiration of contaminated water: a case report. , 1985, Southeast Asian Journal of Tropical Medicine and Public Health.

[145]  W. Tsai,et al.  Pseudomonas pseudomallei infection from drowning: the first reported case in Taiwan , 1985, Journal of clinical microbiology.

[146]  R. Guard,et al.  The prevalence of human melioidosis in Northern Queensland. , 1984, The American journal of tropical medicine and hygiene.

[147]  C. Howe,et al.  The pseudomallei group: a review. , 1971, The Journal of infectious diseases.

[148]  King Cw Chronic or latent melioidosis. , 1971 .

[149]  C. Kingston CHRONIC OR LATENT MELIOIDOSIS , 1971, The Medical journal of Australia.

[150]  P. Morris,et al.  Clinical presentation and medical management of melioidosis in children: a 24-year prospective study in the Northern Territory of Australia and review of the literature. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[151]  F. Castelli,et al.  A case of melioidosis probably acquired by inhalation of dusts during a helicopter flight in a healthy traveler returning from Singapore. , 2015, Journal of travel medicine.

[152]  N. Weisz,et al.  Transient reduction of tinnitus intensity is marked by concomitant reductions of delta band power , 2008 .

[153]  A. Haque,et al.  A critical role for neutrophils in resistance to experimental infection with Burkholderia pseudomallei. , 2007, The Journal of infectious diseases.

[154]  N. Anstey,et al.  Adjunctive granulocyte colony-stimulating factor for treatment of septic shock due to melioidosis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[155]  T. Inglis,et al.  Burkholderia pseudomallei traced to water treatment plant in Australia. , 2000, Emerging Infectious Diseases.

[156]  D. Fisher,et al.  Neurological melioidosis. , 2000, Acta tropica.

[157]  N. White,et al.  Susceptibility of Pseudomonas pseudomallei to some newer beta-lactam antibiotics and antibiotic combinations using time-kill studies. , 1994, The Journal of antimicrobial chemotherapy.

[158]  A. J. Clayton,et al.  Melioidosis: a serological survey in military personnel. , 1973, Military medicine.

[159]  W. Fletcher,et al.  Melioidosis, a New Disease of the Tropics. , 1921 .